MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena Congress and Convention Center, Vienna, Austria LSX Investival Showcase Europe 2025, November 17Location: Old Billingsgate, London, United Kingdom Jefferies Global Healthcare Conferenc ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced its partnership with Priority Pass, the world’s leading airport experiences program, is going global. What first launched in North America last year is now being expanded to key international airports across the Middle East and Europe, giving travelers more ways to take care of themselves mid-journey. Through the expanded collaborat ...

Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter 2025Evaxion now has cash on hand to fund its operations and R&D programs into the second half of 2027The exercises have reduced the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 million COPENHAGEN, Denmark, October 30, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a ...

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025 in Atlanta, Georgia. The presentations will highlight preclinical data for BMF-650, Biomea’s next-generation oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), and combination data for icovamenib, the company’s fir ...

Authorization Positions Company to Generate Non-Dilutive, Tax-Free Capital to Support Growth, Innovation, and Sustainable ExpansionBELVIDERE, NJ, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that the New Jersey Economic Development Authority (NJEDA) has preliminarily approved the Company’s application ...

Agreement Strengthens Plug’s Global Portfolio of Utility-Scale Hydrogen and Sustainable Fuel DevelopmentsSLINGERLANDS, N.Y., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced the execution of a binding supply agreement with Allied Biofuels FE LLC (ABF) for up to 2 gigawatts (GW) of Plug’s GenEco PEM electrolyzer systems. The agreement supports ABF’s development of sustainable aviation fuel (SAF), el ...

Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ETPRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and confe ...

NAARDEN, The Netherlands and MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from ...

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity funding ...

All amounts in U.S. dollars unless otherwise stated TORONTO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Onex Partners announced today an agreement by Onex Partners V (“OP V”), together with other founding institutional equity partners in Convex Group Limited (“Convex”), to sell Convex to Onex Corporation (“Onex”) and American International Group, Inc. (“AIG”) for $7 billion. Stephen Catlin, Paul Brand and the Convex management team founded Convex in 2019 as a de novo insurer in partnership with OP V as well as seve ...